A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

Inclusion Criteria:

1. Male or female subjects 20 years of age or older

2. Ability to understand and the willingness to provide written informed consent

3. Suspected of having cardiac disease or undergoing evaluation of cardiac anatomy forcongenital heart disease

4. Negative pregnancy test within 24 hours of the procedure if subject is a woman ofchildbearing potential

Exclusion Criteria:

1. Known right-to-left, bidirectional, or transient right-to-left cardiac shunt(s)

2. Chronic obstructive pulmonary disease

3. Ejection fraction at screening or baseline <40%

4. Uncontrolled serious ventricular arrhythmias or at high risk for arrhythmias due toprolongation of the QT interval (QT corrected by Fridericia's formula >450 msec inmales and >470 msec in females)

5. Clinically significant abnormality in renal and liver function tests (alanineaminotransferase/aspartate aminotransferase >2 × upper limit of normal [ULN]; serumcreatinine > 1.5 × ULN)

6. Known or suspected hypersensitivity to one or more of the ingredients of NH002,perflutren, or other echocardiographic contrast agent

7. Received an investigational compound within 30 days before enrolling in the study

8. Received any contrast agent either intravascularly or orally within 48 hours beforeNH002 administration

9. Pregnant or lactating female (conception during the study should be avoided)

10. Serious medical or psychiatric illness/condition likely, in the judgment of theinvestigator, to interfere with compliance to protocol treatment/research

11. Clinically unstable cardiopulmonary conditions considered not suitable forparticipation in the trial, in the judgment of the investigator

12. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg ordiastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolicblood pressure ≤ 90 mmHg)